Compare Abeona Therapeutics Inc (ABEO) vs Aon PLC (AON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Aon PLC — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Aon PLC trades at $357.16 (market cap $76.85B). The key difference: Aon PLC is far larger — about 205.9× Abeona Therapeutics Inc's market cap, and Aon PLC pays a 0.91% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AON | |
|---|---|---|
Market Cap | $373.32M | $76.85B |
Sector | Health | Financials |
52-Week High | $7.23 | $375.27 |
52-Week Low | $4.17 | $308.22 |
Enterprise Value | $228.22M | $90.91B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AON trades at $359.82, up 0.66% with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 22.54% net income margin and 46.82% ROE, supported by revenue growth to $17.18B in 2025. Analyst consensus is a Buy with a $385.50 price target, and the company continues to innovate with initiatives like the Aon DPX platform launch in 2026.
Outlook remains positive driven by AI integration and strategic growth, though risks include debt levels and market volatility. The stock offers upside potential near consensus targets, but investors should monitor execution of the 3x3 plan and competitive pressures in the insurance brokerage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Aon PLC
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →
